QURE has been in the news 353% more than usual
Feb 28, 2026, 3:33 AM
-1.89%
What does QURE do
uniQure NV, headquartered in Amsterdam, specializes in gene therapies and employs 480 staff, focusing on one-time treatments for genetic diseases. Their lead candidates include AMT-061 for hemophilia B and AMT-130 for Huntington's disease.
QURE has been in the news recently: Multiple law firms, including Schall Law Firm and DJS Law Group, have filed class action lawsuits against uniQure N.V. for allegedly misleading investors between September 24 and October 31, 2025. Shareholders who lost money during this period are encouraged to file claims by April 13, 2026.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.